Rockwell Medical, Inc. (RMTI): Total Liabilities
$20.16M
As of 2025-12-31
$21.44M
As of 2026-06-30
-14.7%
3-year compound annual growth
-14.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.16M | -24.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $26.62M | -13.8% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $30.88M | -5.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $32.53M | -29.3% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $46.04M | +5.6% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $43.58M | +81.6% | 2022-04-08, Balance as of period end |
| 2019-12-31 | $24.00M | -5.1% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $25.28M | -2.3% | 2020-03-17, Balance as of period end |
| 2017-12-31 | $25.87M | n/a | 2019-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
Compare RMTI, VRDN, KURA, SPRO side by side · Screen every company in Pharmaceutical Preparations ↗